Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.

被引：2
|
作者：
Mateos, Maria-Victoria
Spencer, Andrew
Nooka, Ajay K.
Pour, Ludek
Weisel, Katja C.
Cavo, Michele
Laubach, Jacob
Cook, Gordon
Iida, Shinsuke
Benboubker, Lotfi
Usmani, Saad Zafar
Yoon, Sung-Soo
Bahlis, Nizar J.
Chiu, Christopher
Schecter, Jordan Mark
Wu, Kaida
Qin, Xiang
Soong, David
Dimopoulos, Meletios A.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy
    Mateos, Maria-Victoria
    Blade, Joan
    Larocca, Alessandra
    Oriol, Albert
    Rodriguez, Paula
    Alegre, Adrian
    Cavo, Michele
    Moreb, Jan S.
    Paner, Agne
    Gabrail, Nashat
    Halka, Kathleen G.
    Hassoun, Hani
    Maisel, Christopher
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Ocio, Enrique M.
    Byrne, Catriona
    Harmenberg, Johan
    Thuresson, Sara
    Nordstrom, Eva
    Lindberg, Jakob
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [32] Real-World Analysis of Treatment Patterns and the Effectiveness and Safety Profile of Daratumumab-Based Regimens in Chinese Patients with Newly Diagnosed or Relapsed/Refractory Multiple Myeloma
    Wang, Luqun
    Yang, Wei
    Wang, Yafei
    Niu, Ting
    Fu, Rong
    Zhong, Yuping
    Qian, Wenbin
    Ding, Kaiyang
    Sun, Kai
    Liu, Hong
    Fang, Baijun
    Liu, Hui
    Li, Yanhui
    Yang, Yishen
    Zhuo, Jianmin
    Chen, Xi
    Cui, Canchan
    Lu, Jin
    BLOOD, 2023, 142
  • [33] EFFECTIVENESS AND SAFETY ANALYSIS OF DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Kumar, Seri A.
    Fe, Bitaube R.
    Hinojosa, Orantos C.
    Gavira, Moreno R.
    Garzon, Lopez S.
    HAEMATOLOGICA, 2021, 106 (10) : 339 - 340
  • [34] Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
    Raje, Noopur S.
    Leleu, Xavier P.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA
    Wang, Jiasheng
    Arroyo-Suarez, Raul
    Dasari, Srilatha
    Sekaran, Kanithra
    Tse, William
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1669 - 1677
  • [36] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Moreb, Jan
    Blade, Joan
    Hassoun, Hani
    Cavo, Michele
    Alegre, Adrian
    Mazumder, Amitabha
    Maisel, Christopher
    Paner, Agne
    Leleu, Xavier
    Zonder, Jeffrey A.
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CANCER RESEARCH, 2019, 79 (13)
  • [37] Efficacy and Safety of Elranatamab by Age and Frailty in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Subgroup Analysis From MagnetisMM-3
    Raje, Noopur
    Leleu, Xavier
    Lesokhin, Alexander
    Mohty, Mohamad
    Nooka, Ajay K.
    Leip, Eric
    Conte, Umberto
    Viqueira, Andrea
    Manier, Salomon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S497 - S497
  • [38] Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma
    Zhang, Tian-tian
    Wang, Sen
    Wan, Ning
    Zhang, Li
    Zhang, Zugui
    Jiang, Jie
    CLINICAL THERAPEUTICS, 2018, 40 (07) : 1122 - 1139
  • [39] HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Norkin, Maxim
    Blade, Joan
    Cavo, Michele
    Hassoun, Hani
    Leleu, Xavier
    Alegre, Adrian
    Maisel, Christopher
    Paner, Agne
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Puig, Noemi
    Harran, John
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S329 - S330
  • [40] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Berenson, James R.
    Silagan, Noemi
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Forouzan, Eli
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Boccia, Ralph V.
    Yang, Honghao Hank
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2020, 136
12345